BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

11654

539524

LALPATHLAB

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

DR. LAL PATH LABS LTD. performance

Today’s low

Today’s high

₹ 2740.50 ₹ 2849.90
₹ 2769.10

52 week low

52 week high

₹ 2201.20 ₹ 3653.95
₹ 2769.10

Open Price

₹ 2778.00

Prev. Close

₹ 2777.80

Volume (Shares)

229867.00

Total traded value

₹ 6365.24

Upper Circuit

₹ 3333.30

Lower Circuit

₹ 2222.30

info

DR. LAL PATH LABS LTD. Share Price Update

As of the latest trading session, DR. LAL PATH LABS LTD. share price is currently at ₹ 2750, which is down by ₹ -27.80 from its previous closing. Today, the stock has fluctuated between ₹ 2740.50 and ₹ 2849.90. Over the past year, DR. LAL PATH LABS LTD. has achieved a return of 16.71 %. In the last month alone, the return has been 15.40 %. Read More...

DR. LAL PATH LABS LTD. fundamentals


  • Market cap (Cr)

    22,956.41

  • P/E Ratio (TTM)

    46.50

  • Beta

    0.47

  • Book Value / share

    255.31

  • Return on equity

    21.42%

  • EPS (TTM)

    59.49

  • Dividend yield

    0.87%

  • Net profit/quarter (Cr)

    148.40

info icon alternate text
  • Market cap (Cr)

    23,018.60

  • P/E Ratio (TTM)

    46.50

  • Beta

    0.43

  • Book Value / share

    255.31

  • Return on equity

    21.42%

  • EPS (TTM)

    59.49

  • Dividend yield

    0.87%

  • Net profit/quarter (Cr)

    148.40

info icon alternate text

DR. LAL PATH LABS LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 577.20
Operating Expense 457.50
Net Profit 148.40
Net Profit Margin (%) 25.71
Earnings Per Share (EPS) 17.80
EBITDA 184.30
Effective Tax Rate (%) -2.41
Particulars DEC 2024 (Values in Cr)
Revenue 569.20
Operating Expense 456.90
Net Profit 105.40
Net Profit Margin (%) 18.51
Earnings Per Share (EPS) 12.65
EBITDA 182.29
Effective Tax Rate (%) 26.60
Particulars SEP 2024 (Values in Cr)
Revenue 583.90
Operating Expense 422.60
Net Profit 135.20
Net Profit Margin (%) 23.15
Earnings Per Share (EPS) 16.24
EBITDA 206.50
Effective Tax Rate (%) 26.24
Particulars JUN 2024 (Values in Cr)
Revenue 534.50
Operating Expense 402.30
Net Profit 122.90
Net Profit Margin (%) 22.99
Earnings Per Share (EPS) 14.76
EBITDA 184.30
Effective Tax Rate (%) 23.66
Particulars MAR 2024 (Values in Cr)
Revenue 520.90
Operating Expense 424.20
Net Profit 80.80
Net Profit Margin (%) 15.51
Earnings Per Share (EPS) 9.70
EBITDA 154.10
Effective Tax Rate (%) 28.62
Particulars MAR 2025 (Values in Cr)
Revenue 2351.60
Operating Expense 1841.80
Net Profit 497.30
Net Profit Margin (%) 21.14
Earnings Per Share (EPS) 59.70
EBITDA 777.00
Effective Tax Rate (%) 19.95
Particulars MAR 2024 (Values in Cr)
Revenue 2125.10
Operating Expense 1708.89
Net Profit 346.70
Net Profit Margin (%) 16.31
Earnings Per Share (EPS) 41.72
EBITDA 646.90
Effective Tax Rate (%) 28.14
Particulars MAR 2023 (Values in Cr)
Revenue 1769.00
Operating Expense 1424.80
Net Profit 292.40
Net Profit Margin (%) 16.52
Earnings Per Share (EPS) 35.28
EBITDA 507.29
Effective Tax Rate (%) 25.17
Particulars MAR 2022 (Values in Cr)
Revenue 1878.80
Operating Expense 1470.89
Net Profit 345.30
Net Profit Margin (%) 18.37
Earnings Per Share (EPS) 41.61
EBITDA 565.50
Effective Tax Rate (%) 25.09
Particulars MAR 2021 (Values in Cr)
Revenue 1490.50
Operating Expense 1167.70
Net Profit 280.10
Net Profit Margin (%) 18.79
Earnings Per Share (EPS) 33.93
EBITDA 458.70
Effective Tax Rate (%) 25.12
Particulars MAR 2024 (Values in Cr)
Book Value / Share 221.53
ROE % 20.61
ROCE % 25.58
Total Debt to Total Equity 0.19
EBITDA Margin 30.47
Particulars MAR 2023 (Values in Cr)
Book Value / Share 199.87
ROE % 15.22
ROCE % 18.51
Total Debt to Total Equity 0.30
EBITDA Margin 26.36
Particulars MAR 2022 (Values in Cr)
Book Value / Share 180.17
ROE % 25.51
ROCE % 29.46
Total Debt to Total Equity 0.25
EBITDA Margin 29.38
Particulars MAR 2021 (Values in Cr)
Book Value / Share 149.39
ROE % 26.03
ROCE % 32.56
Total Debt to Total Equity 0.07
EBITDA Margin 30.84
Particulars MAR 2020 (Values in Cr)
Book Value / Share 126.81
ROE % 23.01
ROCE % 31.44
Total Debt to Total Equity 0.00
EBITDA Margin 29.96
Particulars MAR 2024 (Values in Cr)
Book Value / Share 227.56
ROE % 21.42
ROCE % 25.77
Total Debt to Total Equity 0.12
EBITDA Margin 31.49
Particulars MAR 2023 (Values in Cr)
Book Value / Share 202.70
ROE % 18.49
ROCE % 20.93
Total Debt to Total Equity 0.21
EBITDA Margin 28.68
Particulars MAR 2022 (Values in Cr)
Book Value / Share 176.63
ROE % 25.68
ROCE % 29.35
Total Debt to Total Equity 0.16
EBITDA Margin 30.10
Particulars MAR 2021 (Values in Cr)
Book Value / Share 146.03
ROE % 25.08
ROCE % 31.55
Total Debt to Total Equity 0.02
EBITDA Margin 30.77
Particulars MAR 2020 (Values in Cr)
Book Value / Share 124.83
ROE % 22.92
ROCE % 31.14
Total Debt to Total Equity 0.00
EBITDA Margin 30.26
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 830.31
Total Assets 2455.96
Total Liabilities 2455.96
Total Equity 1885.36
Share Outstanding 83477852
Price to Book Ratio 9.94
Return on Assets (%) 14.56
Return on Capital (%) 18.17
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 665.41
Total Assets 2385.56
Total Liabilities 2385.56
Total Equity 1699.54
Share Outstanding 83367877
Price to Book Ratio 9.02
Return on Assets (%) 10.01
Return on Capital (%) 12.34
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 617.59
Total Assets 2346.75
Total Liabilities 2346.75
Total Equity 1537.06
Share Outstanding 83344877
Price to Book Ratio 14.76
Return on Assets (%) 14.69
Return on Capital (%) 18.32
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 926.02
Total Assets 1661.33
Total Liabilities 1661.33
Total Equity 1276.01
Share Outstanding 83344877
Price to Book Ratio 18.54
Return on Assets (%) 17.55
Return on Capital (%) 22.85
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 569.11
Total Assets 1374.30
Total Liabilities 1374.30
Total Equity 1054.02
Share Outstanding 83344877
Price to Book Ratio 11.23
Return on Assets (%) 16.44
Return on Capital (%) 21.44
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 683.11
Total Assets 2415.44
Total Liabilities 2415.44
Total Equity 1899.66
Share Outstanding 83477852
Price to Book Ratio 9.94
Return on Assets (%) 15.91
Return on Capital (%) 19.38
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 534.21
Total Assets 2320.17
Total Liabilities 2320.17
Total Equity 1689.86
Share Outstanding 83367877
Price to Book Ratio 9.02
Return on Assets (%) 12.60
Return on Capital (%) 15.18
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 542.90
Total Assets 2210.78
Total Liabilities 2210.78
Total Equity 1472.11
Share Outstanding 83344877
Price to Book Ratio 14.76
Return on Assets (%) 15.61
Return on Capital (%) 19
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 888.63
Total Assets 1573.07
Total Liabilities 1573.07
Total Equity 1217.08
Share Outstanding 83344877
Price to Book Ratio 18.54
Return on Assets (%) 17.80
Return on Capital (%) 23.01
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 549.19
Total Assets 1317.93
Total Liabilities 1317.93
Total Equity 1016.28
Share Outstanding 83344877
Price to Book Ratio 11.23
Return on Assets (%) 16.93
Return on Capital (%) 21.96
Particulars MAR 2024 (Values in Cr)
Net Income 362.29
Cash from Operations 667.36
Cash from Investing -24.26
Cash from Financing -413.86
Net change in Cash 97.20
Free Cash Flow 718.53
Particulars MAR 2023 (Values in Cr)
Net Income 241.07
Cash from Operations 562.46
Cash from Investing -287.30
Cash from Financing -283.18
Net change in Cash -114.46
Free Cash Flow 598.97
Particulars MAR 2022 (Values in Cr)
Net Income 350.29
Cash from Operations 576.72
Cash from Investing -449.24
Cash from Financing 136.45
Net change in Cash 133.89
Free Cash Flow 670.82
Particulars MAR 2021 (Values in Cr)
Net Income 296.47
Cash from Operations 499.85
Cash from Investing -212.01
Cash from Financing -138.55
Net change in Cash 47.57
Free Cash Flow 535.41
Particulars MAR 2020 (Values in Cr)
Net Income 227.58
Cash from Operations 377.36
Cash from Investing -26.11
Cash from Financing -190.44
Net change in Cash 67.33
Free Cash Flow 424.49
Particulars MAR 2024 (Values in Cr)
Net Income 384.37
Cash from Operations 603.02
Cash from Investing 31.91
Cash from Financing -403.99
Net change in Cash 105.51
Free Cash Flow 647.91
Particulars MAR 2023 (Values in Cr)
Net Income 292.35
Cash from Operations 526.65
Cash from Investing -288.47
Cash from Financing -270.04
Net change in Cash -130.98
Free Cash Flow 558.36
Particulars MAR 2022 (Values in Cr)
Net Income 345.25
Cash from Operations 543.25
Cash from Investing -448.53
Cash from Financing 141.24
Net change in Cash 118.43
Free Cash Flow 606.34
Particulars MAR 2021 (Values in Cr)
Net Income 280.10
Cash from Operations 470.47
Cash from Investing -195.19
Cash from Financing -135.74
Net change in Cash 42.42
Free Cash Flow 498.52
Particulars MAR 2020 (Values in Cr)
Net Income 223.18
Cash from Operations 361.15
Cash from Investing -19.47
Cash from Financing -187.22
Net change in Cash 65.29
Free Cash Flow 404.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 76.41 13.35 100103.60 5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED 75.38 183.85 4.73 141.28 51.01 / 98.70
SHREE PACETRONIX LTD. 70.00 14.58 1.87 25.20 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.68 0.00 2.57 27.88 3.22 / 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 83.30 12.22 100103.60 5690.80 / 7545.10
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 32.25 0.00 -17.27 24.09 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5560.50 29.47 6.24 6083.19 3750.00 / 6400.00

DR. LAL PATH LABS LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2769.10 -0.31 redarrow
red-green-graph indicator
5 Bearish
11 Bullish
  • 5 Days 2788.80
  • 26 Days 2680.00
  • 10 Days 2763.60
  • 50 Days 2665.60
  • 12 Days 2749.90
  • 100 Days 2734.40
  • 20 Days 2702.30
  • 200 Days 2788.10
2794.00 PIVOT

First Support

2736.40

First Resistance

2835.40

Second Support

2695.00

Second Resistance

2893.00

Third Support

2637.40

Third Resistance

2934.40

RSI

57.83

ADX

27.23

MACD

69.83

Williams % R

-39.96

Commodity Channel Index (CCI)

64.83

Date

2025-04-30

Week

121563.00

Same Day

117671.00

Month

137389.00

1 Year

0.47

3 Year

0.56

Over 1 Month

15.40%

down

Over 1 Year

16.71%

down

Over 3 Months

-3.77%

down

Over 3 Years

3.59%

down

Over 6 Months

-9.04%

down

Over 5 Years

11.79%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

DR. LAL PATH LABS LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
6.1%
Promoter Holdings
53.9%
FII
23.9%
DII
16.08%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Arvind Lal 2.5745443E7 (30.8%) Shareholding of Promoter and Promoter Group
Vandana Lal 1.6082327E7 (19.24%) Shareholding of Promoter and Promoter Group
Invesco Oppenheimer International Growth Fund 2943012.0 (3.52%) Public Shareholding
Hdfc Trustee Company Limited-hdfc Flexi Cap Fund 2701968.0 (3.23%) Public Shareholding
Uti-flexi Cap Fund 1939907.0 (2.32%) Public Shareholding
Anjaneya Lal 1689614.0 (2.02%) Shareholding of Promoter and Promoter Group
Archana Lal Erdmann 1543751.0 (1.85%) Shareholding of Promoter and Promoter Group
Sbi Large & Midcap Fund 1424171.0 (1.7%) Public Shareholding
Nippon Life India Trustee Ltd-a/c Nippon India Small Cap Fund 1400807.0 (1.68%) Public Shareholding
Life Insurance Corporation Of India 1231246.0 (1.47%) Public Shareholding
Smallcap World Fund, Inc 1227272.0 (1.47%) Public Shareholding
The Brown Capital Management International Small Company Fund 1123786.0 (1.34%) Public Shareholding
Indus India Fund (mauritius) Limited 852486.0 (1.02%) Public Shareholding

News

Left Arrow
Right Arrow

DR. LAL PATH LABS LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
13 Feb 2024 12.0 Interim 2 13 Feb 2024 Equity shares
11 Aug 2023 6.0 Final 11 Aug 2023 Equity shares
11 Aug 2023 6.0 Interim 11 Aug 2023 Equity shares
05 Aug 2022 6.0 Interim 09 Aug 2022 Equity shares
22 Jun 2022 6.0 Final 23 Jun 2022 Equity shares
18 Aug 2021 6.0 Interim 22 Aug 2021 Equity shares
20 Jul 2021 8.0 Final 22 Jul 2021 Equity shares
09 Feb 2021 6.0 Interim 2 10 Feb 2021 Equity shares
18 Nov 2020 6.0 Interim 19 Nov 2020 Equity shares
05 Mar 2020 6.0 Interim 2 06 Mar 2020 Equity shares
20 Nov 2019 6.0 Interim 21 Nov 2019 Equity shares
02 Aug 2019 3.5 Final 06 Aug 2019 Equity shares
19 Nov 2018 2.5 Interim 20 Nov 2018 Equity shares
03 Aug 2018 3.0 Final 07 Aug 2018 Equity shares
20 Nov 2017 1.5 Interim 21 Nov 2017 Equity shares
12 Jul 2017 1.7 Final 14 Jul 2017 Equity shares
13 Feb 2017 1.3 Interim 14 Feb 2017 Equity shares
20 Jul 2016 2.45 Final 22 Jul 2016 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
10 Jun 2024 6.0 Final 10 Jun 2024 Equity shares
13 Feb 2024 12.0 Interim 2 13 Feb 2024 Equity shares
11 Aug 2023 6.0 Final 11 Aug 2023 Equity shares
11 Aug 2023 6.0 Interim 11 Aug 2023 Equity shares
05 Aug 2022 6.0 Interim 09 Aug 2022 Equity shares
22 Jun 2022 6.0 Final 23 Jun 2022 Equity shares
18 Aug 2021 6.0 Interim 22 Aug 2021 Equity shares
20 Jul 2021 8.0 Final 22 Jul 2021 Equity shares
09 Feb 2021 6.0 Interim 2 10 Feb 2021 Equity shares
18 Nov 2020 6.0 Interim 19 Nov 2020 Equity shares
05 Mar 2020 6.0 Interim 2 06 Mar 2020 Equity shares
20 Nov 2019 6.0 Interim 21 Nov 2019 Equity shares
02 Aug 2019 3.5 Final 06 Aug 2019 Equity shares
19 Nov 2018 2.5 Interim 20 Nov 2018 Equity shares
03 Aug 2018 3.0 Final 07 Aug 2018 Equity shares
20 Nov 2017 1.5 Interim 21 Nov 2017 Equity shares
12 Jul 2017 1.7 Final 14 Jul 2017 Equity shares
13 Feb 2017 1.3 Interim 14 Feb 2017 Equity shares
20 Jul 2016 2.45 Final 22 Jul 2016 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

DR. LAL PATH LABS LTD. Share Price

Dr. Lal PathLabs Limited was incorporated as a Private Limited Company with the name Dr. Lal PathLabs Private Limited', on February 14, 1995 at Delhi. The business of the Partnership Firm, Central Clinical Laboratory was undertaken by the Company. The Company converted into a Public Limited Company and name of the Company was changed to Dr. Lal PathLabs Limited' vide fresh Certificate of Incorporation granted by the RoC on August 19, 2015.

Dr Lal PathLabs is among the most trusted diagnostic healthcare service provider in India, offering services through over 5000 diagnostic tests and related healthcare services through a nationwide network of medical laboratory centres. Through its integrated, nationwide network, the Company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Presently, the Company is engaged the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. The Company has built a national, 'hub and spoke' network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 371 other clinical laboratories, 5,102 patient service centers and 10,938 pickup points as of 31 March 2023. Its customers include individual patients, hospitals and other healthcare providers and corporate customers. Apart from these, the catalogue of services includes 481 test panels, 2763 pathology tests and 1947 radiology and cardiology tests.

Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s. Central Clinical Laboratory and M/s. Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company 'Dr Lal Pathlabs Pvt. Ltd.'

The Board of Directors of Dr. Lal PathLabs at its meeting held on 12 May 2017 approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited, a wholly owned subsidiary of the Company with the Company with effect from 1 April 2017. The Scheme was sanctioned by the New Delhi and Ahmedabad Bench of Hon'ble National Company Law Tribunal (NCLT), on October 23, 2018 and December 11, 2018 respectively. Pursuant thereto, in accordance with the terms of the scheme, Delta Ria And Pathology Private Limited was amalgamated with Dr. Lal PathLabs Limited w.e.f. April 1, 2017.

The Board of Directors of Dr. Lal PathLabs at its meeting held on 7 August 2017 approved acquisition of 70% stake in Dr. Lal Path Labs Bangladesh (Pvt) Limited (DLPLB) from existing shareholders. Prior to investment in the company by Dr. Lal PathLabs, DLPLB shall be acquiring the running diagnostic business of a sole-proprietorship firm in Dhaka, Bangladesh.

On 12 December 2017, Dr. Lal PathLabs announced that the Board of Directors of the company's subsidiary Paliwal Diagnostics Private Limited, at its meeting held on 12 December 2017 approved acquisition of a proprietary concern viz. Satya Pathology and Diagnostic Centre (SPDC) based out of Kanpur. SPDC clocked turnover of Rs 1.46 crore in FY 2017.

Dr. Lal PathLabs' Kolkata Reference Lab started testing of samples in early January 2018. The World-class Lab will cater the demand from Northeast as well as Eastern regions of India. It will also cater to neighboring international arena.

During the FY2019, Dr. Lal Ventures Private Limited and PathLabs Unifiers Private Limited were incorporated on December 10 and December 12, 2018, respectively, as wholly owned subsidiaries of the Company. As on 31 March 2019,the company has 5 domestic and 3 overseas subsidiaries under its roof.

The Board of Directors of your Company in their meeting held on February 3, 2020, approved a Scheme of Amalgamation ('the Scheme') between the Company and APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of the Company. The Company is in the process of filing a petition Application before the National Company Law Tribunal, New Delhi for approval of the Scheme of Amalgamation.

During the FY2020, Company's Wholly Owned Subsidiary viz M/s. PathLabs Unifiers Private Limited acquired 70% equity stake in M/s Centrapath Labs Private Limited and M/s. APRL PathLabs Private Limited consequent upon which both these Companies became subsidiaries of the Company. Also Dr. Lal PathLabs Kenya Private Limited was incorporated on August 6, 2019, as a Wholly Owned Subsidiary of the Company in Kenya. The Company has subscribed to equity share capital amounting to KES 10 million (Rs 7.10 million) consisting of 9,880 shares of KES 100.

As on 31 March 2020,the company has 7 domestic and 4 overseas subsidiaries under its roof.

During the year 2019-20, the Company has made a further investment of Rs 599.00 million and Rs 9.00 million in this subsidiary Company Pathlabs Unifiers Private Limited and Dr. Lal Ventures Private Limited respectively through subscription of additional shares.

During the quarter ended 30 June 2020,the company has made a further investment of Rs 15 million in its whollyowned subsidiary Pathlabs Unifiers Private Ltd,through subscription of additional equity shares.

Subsequent to the quarter ended 30 September 2020,pursuant to approval of the Board of Directors of Pathlabs Unifiers Private Ltd(PUPL),a wholly owned subsidiary,PUPL has signed binding term sheets on 06 November 2020,for the acquisition of the business of Bindish Diagnostic Laboratory LLP, Gujarat,on a going concern basis,for a purchase consideration not exceeding Rs 40 million and equity stake of 40% in ChanRe Diagnostic Services Private Ltd,Bengaluru,for a purchase consideration not exceeding Rs 175 million. Both of these companies are engaged in providing pathological diagnostic services.

During year 2020-21, the Company added 15 labs, 600 collection center and 2200 pick-up points. It had overall 231 clinical labs, 3,705 patient service centres and 9,247 pickup-up points as on March 31, 2021.

The Board of Directors of the Company in their meeting on February 3, 2020, approved a Scheme of Amalgamation between Dr. Lal PathLabs Limited (the Transferee Company) and APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of the Company (Transferor Company), which was sanctioned on May 13, 2022 and the appointed date for the Scheme is April 1, 2020.

During the year 2021-22, the Company acquired 100% stake in M/s Suburban Diagnostics (India) Private Limited and consequently, Suburban became a Wholly Owned Subsidiary of the Company, effective November 12, 2021. It introduced 46 labs, 1,026 patient service centers and 1,352 pick-up points.

The Company opened its Reference Lab at Vidyavihar, in Mumbai in Jan' 23. Dr. Lal PathLabs expanded its National Reference Lab in Rohini, Delhi, by acquiring a second electron microscope, an upgraded lab information system and advanced tools such as artificial intelligence and data mining.

During FY 2023, the Company operated a network of 277 clinical labs, including the prestigious National Reference Lab in Delhi and the Regional Reference Lab in Kolkata, Bangalore and Mumbai. Additionally, with 5,102 Patient Service Centres (PSCs) and 10,938 Pick-up Points (PUPs), the Company has established a nationwide presence. APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of Company (APL/ Transferor Company), was amalgamated with Dr. Lal PathLabs Limited (the Company/ Transferee Company) effective on March 27, 2023. The Company launched 134 tests in FY' 23 to expand the Super Specialty Portfolio.

In 2024, Company introduced the pioneering Histocompatibility and Transplant Immunology testing with Next Generation Sequencing (NGS), which facilitated over 600 runs of HLA-NGS, for analysing 27,000 samples of Bone Marrow and Solid Organ Transplantation
in India, Africa, Bangladesh and Nepal. It also established the donor-derived cell-free DNA' as a non-invasive monitoring test for solid organ transplantation .

Parent organization Indian Private
NSE symbol LALPATHLAB
Founded 1995
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Dr Lal Pathlabs Ltd?

Answer Field

The share price of Dr Lal Pathlabs Ltd for NSE is ₹ 2750 and for BSE is ₹ 2757.45.

What is the Market Cap of Dr Lal Pathlabs Ltd?

Answer Field

The market cap of Dr Lal Pathlabs Ltd for NSE is ₹ 2,29,56.41 Cr. and for BSE is ₹ 2,30,18.60 Cr. as of now.

What is the 52 Week High and Low of Dr Lal Pathlabs Ltd?

Answer Field

The 52 Week High and Low of Dr Lal Pathlabs Ltd for NSE is ₹ 3653.95 and ₹ 2201.20 and for BSE is ₹ 3645.00 and ₹ 2210.00.

How to Buy Dr Lal Pathlabs Ltd share?

Answer Field

You can trade in Dr Lal Pathlabs Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Dr Lal Pathlabs Ltd?

Answer Field

The 1 year returns on the stock has been 16.71%.

What is the Current Share Price of Dr Lal Pathlabs Ltd?

Answer Field

Dr Lal Pathlabs Ltd share price is for NSE ₹ 2750 & for BSE ₹ 2757.45 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Dr Lal Pathlabs Ltd Share?

Answer Field

The market cap of Dr Lal Pathlabs Ltd for NSE ₹ 2,29,56.41 & for BSE ₹ 2,30,18.60 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Dr Lal Pathlabs Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Dr Lal Pathlabs Ltd share is 46.50.

What is the PB ratio of Dr Lal Pathlabs Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Dr Lal Pathlabs Ltd share is 255.31.

How to Buy Dr Lal Pathlabs Ltd Share?

Answer Field

You can trade in Dr Lal Pathlabs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Dr Lal Pathlabs Ltd Share on Bajaj Broking App?

Answer Field

To buy Dr Lal Pathlabs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Dr Lal Pathlabs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|